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Abstract High-throughput testing of drugs across molecular-characterised cell lines can identify
candidate treatments and discover biomarkers. However, the cells’ response to a drug is typically
quantified by a summary statistic from a best-fit dose-response curve, whilst neglecting the
uncertainty of the curve fit and the potential variability in the raw readouts. Here, we model the
experimental variance using Gaussian Processes, and subsequently, leverage uncertainty estimates
to identify associated biomarkers with a new Bayesian framework. Applied to in vitro screening
data on 265 compounds across 1074 cancer cell lines, our models identified 24 clinically established
drug-response biomarkers, and provided evidence for six novel biomarkers by accounting for
association with low uncertainty. We validated our uncertainty estimates with an additional drug
screen of 26 drugs, 10 cell lines with 8 to 9 replicates. Our method is applicable to any dose-
response data without replicates, and improves biomarker discovery for precision medicine.
Introduction
The failure rate for new drugs entering clinical trials is in excess of 90%, with more than a quarter of
drugs failing due to lack of efficacy (Arrowsmith and Miller, 2013; Cook et al., 2014). The rapid
development of technologies for deep molecular characterisation of clinical samples holds the prom-
ise to uncover molecular biomarkers that stratify patients towards more efficacious drugs, a corner-
stone of precision medicine. In oncology, we can identify potential biomarkers of drug response in
high-throughput screens (HTS) of patient-derived cell lines; these biomarkers need to be then vali-
dated in patients.
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Assessment of cell line drug response typically involves treatment with multiple concentrations of
the compound, followed by measurement of the amount of viable cells after a fixed period of time
for each dose, and derivation of a dose-response curve. The drug response is commonly then sum-
marised by measurements taken from this curve, most often the concentration required to reduce
cell viability by half that is IC50, or the area under the curve that is AUC. Currently the two largest in
vitro drug screening studies, the Genomics of Drug Sensitivity in Cancer (GDSC) (Garnett et al.,
2012; Iorio et al., 2016) and the Cancer Therapeutics Response Portal (CTRP) Rees et al., 2016
have shown that some clinically-actionable biomarkers of drug response can be concordantly discov-
ered (Iorio et al., 2016; Seashore-Ludlow et al., 2015), and that different properties and mecha-
nisms of drug response are best captured by different metrics dependent on the dose-response
curve (Fallahi-Sichani et al., 2013).
Most HTS efforts focus on increasing throughput (Iorio et al., 2016; Seashore-Ludlow et al.,
2015) and thereby often neglect experimental replicates, which renders it impossible to correct for
experimental noise, resulting in uncertainty for the estimated drug-response metrics (e.g. IC50 value).
Extrapolating IC50 values beyond the tested drug concentration range is particularly challenging and
often unaccounted for in quality control metrics (Haibe-Kains et al., 2013; Haverty et al., 2016).
Most published studies using machine learning algorithms or mechanistic models for predicting drug
response and biomarkers assume that the measured drug responses are precise (Costello et al.,
2014; Keshava et al., 2019; Menden et al., 2019; Silverbush et al., 2017). If this assumption is not
met and there is high uncertainty in the measured drug-response values, the utility of these methods
for enhancing drug development may be severely limited (Costello et al., 2014; Menden et al.,
2019; Silverbush et al., 2017). Experimental noise can be reduced by adding experimental repli-
cates, however, this either reduces the throughput of the screen or increases the cost. Most current
models for curve fitting and describing dose-response data have primarily assumed that cell viability
has a sigmoidal relationship to the logarithm of the dose concentrations of the drug (Dawson et al.,
2012; Wang et al., 2010). Whilst some models are more flexible by allowing many inflection points
in the dose-response curve (Di Veroli et al., 2016; Vis et al., 2016), their main output is a single
drug-response value that does not fully capture the uncertainty in the measurements (Fallahi-
Sichani et al., 2013).
Gaussian Processes (GP) are a flexible, probabilistic modelling technique that has been success-
fully used to measure uncertainty in noisy gene expression datasets (Lopez-Lopera and Alvarez,
2019) and has been incorporated into machine learning prediction of cell fates (Boukouvalas et al.,
2018). This technique has been shown to cope well with regression tasks on dependent data and
high dimensional covariates (Rasmussen and Williams, 2005; Shi and Choi, 2011). Instead of fitting
a single function to the data, GPs allow for a flexible range of beliefs about the function underlying
the data (Tian et al., 2017). In the case of cell line drug responses, this can be conceptualised as fit-
ting a range of curves that have equivalently strong fit to the data. We can sample from the inferred
posterior distribution over functions, that is the variance between these curves, to generate uncer-
tainty estimates of quantities of interest, in our case, properties of the dose-response such as IC50.
GPs have been recently utilised to identify and guide experimental validation of compounds, on
top of being applied to protein engineering and imputing gene expression values (Hie et al., 2020).
GPs have also been used in conjunction with neural networks to model dose-response curves as a
function of molecular markers (Tansey et al., 2018). The main objective in this work was to predict
drug response using the molecular measurements, and the non-linear nature of the prediction model
makes interpretation for the purpose of biomarker detection challenging. By contrast, we aimed to
develop a model that could provide interpretable summary statistics with uncertainty estimates that
can be flexibly used to improve biomarker detection.
In this study, we therefore introduce a new GP regression approach for describing dose-response
relationships in cancer cell lines that quantifies the uncertainty of the model fitted to measured
responses for each single experiment, and we show that estimates of IC50 values within the tested
concentration range correlates with confidence intervals obtained experimentally from replicate
experiments. Subsequently, we use our new dose-response model to identify genetic sensitivity and
resistance biomarkers in standard statistical tests (e.g. ANOVA). We demonstrate how the flexibility
of the GP dose-response modelling can be further exploited in a Bayesian framework to identify
novel biomarkers. We also describe the variation in the level of drug response uncertainty across
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cancer types and drug classes. By accounting for the uncertainty in dose-response experiments,
detection of clinically-actionable biomarkers can be enhanced.
Results
A probabilistic framework for measuring dose-response and predicting
biomarkers
We analysed in vitro screening data on 265 compounds across 1,074 cell lines (Iorio et al., 2016). In
those experiments, we quantified the amount of cytotoxicity after four days of compound treatments
at each dose compared to controls (Figure 1A). The relationship between the dose and response
(decrease in cell viability) was first described using a dose-response curve derived with a sigmoidal
Figure 1. Workflow for fitting of Gaussian Process models to dose-response curves and estimating their uncertainty. (A) Large-scale drug screens test
cell lines with different drugs and at different doses are used to obtain dose-response data. (B) Typically, for each drug tested in a cell line, the sigmoid
model is fit to the drug-response data and (C) the overall measures of response (IC50, AUC, etc.) are extracted. (D) For each drug tested in a cell line,
we fit a GP model to the dose-response data. The GP allows us to sample from a distribution of possible dose-response curves, obtaining a measure of
uncertainty. (E) From these curves, we can extract overall measures of response, such as IC50, and importantly, their 95% confidence intervals. (F)
Mutation markers for each cell line can be determined based on presence/absence of single nucleotide polymorphisms (SNPs) in key genes. Both the
drug-response estimates and the mutation markers are used to compute (G) the F-statistic for ANOVA, and (H) Bayesian test for biomarker association.
The drug-response summary measure gi for cell line i is modelled via a cell line- specific mean mi and standard error si. The mean is defined as a linear
effect b of the biomarker status zi and a further effect g from any remaining covariates xi, such as tissue type. The parameter s* is the standard
deviation of mi. (I) Boxplots illustrate the differences in the estimated mean IC50 of ERBB2 amplified and non-amplified breast cancer cell lines treated
with afatinib. An ANOVA test was used to test this difference in means but did not consider uncertainty in each IC50 estimate. (J) We estimated
posterior distributions of gene association using the Bayesian model, that is the effect of a genetic mutation on the IC50 measurement of drug
response. Distributions centred on zero indicate no effect whilst distributions on either side of zero indicate positive or negative effects of mutations on
drug response.
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function (Figure 1B and C). This assumes that the number of viable cells decreases at an exponential
rate, then slows down and eventually plateaus at a lower limit. Since it was costly to test all possible
doses, the sigmoid function was used to extrapolate the response at concentrations that had not
been tested and to estimate overall measures of response, such as IC50 or AUC values, for down-
stream analysis. However, considering that each experiment tested only between five and nine dos-
age concentrations per experiment in GDSC, and a maximum of 16 in CTRP, the tightness of fit of
the dose-response curve to the data points and therefore the level of uncertainty about the inferred
response may vary. We utilised the probabilistic nature of GP models to quantify the uncertainty in
the dose-response experiments as an alternate approach (Figure 1D). We sampled from the fitted
GP and used the posterior distribution to quantify the uncertainty in curve fits for each experiment.
We again generated summary statistics, IC50 and AUC values, by taking the average of the GP sam-
ples and also quantified the level of uncertainty for these statistics (Figure 1E). The GP model has
the advantage that it models outliers at higher doses as one component of a two-component Beta
mixture in the model (see Materials and methods). Such outliers are typically the result of an experi-
mental failure, and cannot be modelled using simple Gaussian noise without over-estimating the
noise parameter.
After fitting the dose-response data using the sigmoid and GP models, we tested various bio-
marker hypotheses by examining the association between the overall response statistics from the
models with genetic variants detected in the cell lines using a frequentist and a Bayesian approach
(Figure 1F–H). For one biomarker hypothesis, as an example, we examined copy number alterations
and point mutations in breast cancer cell lines in relation to the measured drug response of afatinib
in those cells. The GP and sigmoid estimated IC50 from cell lines treated with afatinib were signifi-
cantly different in cases with and without ERBB2 amplification (ANOVA q-value = 4.12e-9;
Figure 1I). The GP models provided an added benefit of providing uncertainty estimates that were
incorporated into a Bayesian hierarchical model to further verify the association between ERBB2
amplification and afatinib sensitivity (posterior probability = 0.001; Figure 1J).
Gaussian Processes provide estimates of dose-response uncertainty for
single experiments
Both GP and sigmoid curve fitting produced comparable IC50 and AUC estimates. Precursor sigmoid
curve fitting methods based on Markov Chain Monte Carlo simulations enabled error estimates in
IC50 values (Garnett et al., 2012), however, this was neglected in the state-of-the-art sigmoid curve
fitting (Vis et al., 2016) due to missing propagation to biomarker identification. Here, we introduce
the added benefit of sampling from the GP posterior, which provides the models in-build uncertainty
obtained for these IC50 estimates. This is important for high-throughput drug screening experiments
where there is often a high number of drugs and samples tested but very few replicate experiments.
By applying the GP model to each experiment, we estimated the standard deviation for each IC50 or
AUC value based only on data points from that single experiment. These single sample standard
deviations were compared to the standard deviations measured from here provided replicate experi-
ments, that is the same drug tested multiple times on the same cell line and at the same concentra-
tion. We applied our GP estimation method to data from replicate experiments of 26 drugs on 10
cell lines, which contained 260 test conditions and 8 to 9 replicates for each condition. We wanted
to see if an estimate of the uncertainty of the summary statistic, such as the standard deviation of
the IC50 posterior samples, would be correlated with the dispersion between replicates. Here, we
refer to the variability between (mean) estimates for replicates as the observation uncertainty, and
the variability in the estimate for a single replicate as the estimation uncertainty.
We compared observation and estimation uncertainty across replicate experiments of all 260 con-
ditions (Figure 2A). When the estimation uncertainty is large, we will have less confidence in the esti-
mated IC50 in an experiment. Measurement errors for individual points in a dose-response curve will
generally result in larger estimation uncertainty, whereas greater variation between biological repli-
cates will result in larger observation uncertainty. We found two trends in the relationship between
observation and estimation uncertainty. First, for experiments where the estimated IC50 lies within
the concentration range tested, the estimation uncertainty is positively correlated (Pearson correla-
tion = 0.84, 95% CI [0.76, 0.89]) with the observation uncertainty. Second, for experiments where
the estimated IC50 lies beyond the maximum tested concentration, we observed a negative correla-
tion (Pearson correlation =  0.39, 95% CI [ 0.51,–0.25]). We note that the latter experiments
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Figure 2. Comparison of GP estimates of uncertainty to replicate drug screening experiments. (A) Comparison between observational uncertainty
(standard deviation over replicates of log10(IC50) mean estimates) and estimation uncertainty (average over replicates of log10(IC50) standard deviation)
from each replication experiment. The colour of the points indicates whether the log10(IC50) mean estimates were within or outside the maximum
concentration range for each assay. (B) Mean IC50 and the estimation uncertainty from the GPs for a BRAF inhibitor (dabrafenib) tested in each cell line
Figure 2 continued on next page
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require extrapolation to estimate the IC50 beyond the concentration range, which increases the esti-
mation uncertainty, but does not generally affect the observational uncertainty. However, we
observed that the estimation uncertainty from our GPs for dabrafenib (BRAF inhibitor) tested in two
independent studies on the same cell lines were comparable both within and beyond the concentra-
tion range (Figure 2B).
Since the replicate experiments were conducted in batches over a period of several months, we
verified that the observed trends held regardless of batches (Figure 2—figure supplement 1). Addi-
tionally, we examined the relationship between estimation uncertainty and observation uncertainty
in a number of edge cases where IC50 was estimated within and beyond the maximum concentration
tested (Figure 2C–E). In the case of olaparib tested on PC-14, the uncertainty for the IC50 within
each replicate experiment was high, and this level of uncertainty was consistent across all replicates
even beyond the max concentration (Figure 2C and F). In other replicate experiments, both estima-
tion and observation uncertainty were low (Figure 2D and G), or varied depending on whether the
batch reported mostly IC50 values beyond the concentration range. Talazoparib tested in colorectal
cancer line HCT-15 is a case where observation uncertainty was high, even though estimation uncer-
tainty was low, and experiments in different batches showed different estimated IC50s from very dif-
ferent dose-response curves (Figure 2E and H).
In order to examine the diversity of uncertainty estimates across experiments further, we
described the relationship between AUC value of GP fits with their corresponding estimation uncer-
tainty (Figure 3). We decided to use AUC here due to the greater uncertainty of estimating IC50s
beyond the maximum dose concentration. Since AUCs were computed within the tested concentra-
tion range, the estimation uncertainty for AUC was not substantially higher for cases where IC50s
were estimated within compared to beyond the maximum concentration (Figure 3—figure supple-
ment 1A). The difference between the AUC estimates from the GP compared to the published
GDSC sigmoid curve fits was greatest for experiments showing a partial response (AUC between 0.4
and 0.9), whilst at the same time these experiments also had the highest estimation uncertainty
(Figure 3A). Our visual examination of the raw dose-response data from those experiments revealed
evidence of poor quality readouts, for instance, where cell viability increases with increasing drug
dose (Figure 3—figure supplement 1B). We were able to quantify the quality of these readouts by
estimating the Spearman correlation coefficient based on the raw cell viability counts and the dose
concentrations (Figure 3B). A negative Spearman correlation indicates that cell viability decreases as
dosage increases (as expected) whilst a positive Spearman correlation indicates the opposite. The
experiments with high estimation uncertainty from our GPs were also the experiments with high
Spearman correlation pointing to poor quality.
Next, we investigated whether there were any attributes of experiments that would correspond
to high estimation uncertainty and poor quality results. Labelling of experiments based on cell cul-
ture conditions, dose and cancer type revealed no obvious associations with estimation uncertainty
(Figure 3—figure supplement 2A–E). However, there was a large spread in the uncertainty esti-
mates for AUC when we grouped the experiments into target pathways based on the primary tar-
gets of the tested drugs (Figure 3C; Figure 3—figure supplement 2F). Whilst most drugs had
similar average AUC point estimates between 0.6 and 0.8, suggesting they all had a spread of
Figure 2 continued
in two independent studies (GDSC and CTD2). Estimation uncertainty (error bars and grey shading) were larger beyond the max concentration in both
GDSC (dashed line) and CTD2 (grey line). The point estimates of the IC50s from the GPs (black dots) were also comparable to the published IC50s (red
dots). (C-E) Three sets of replicate experiments, representing different amounts of estimation and observation uncertainty. Each density represents the
distribution of IC50 values from the Gaussian process samples from each replicate experiment. The colours represent different experimental batches.
Narrow distributions demonstrate low estimation uncertainty and overlapping distributions demonstrate low observation uncertainty. The thick black
line represents the density obtained by pooling samples from all replicates and the dashed line shows the maximal dosage tested. GP-curve fits
corresponding to the three sets of replicate experiments showing IC50 estimates with (F) high uncertainty, (G) low uncertainty, and (H) mix of
uncertainties depending on whether estimates are made within or beyond the max concentration. The blue areas represent the 95% confidence interval
in the curve fits and extrapolated GP curves (light grey lines) are displayed up to five times the maximum concentration, where the uncertainty will be
extremely high.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Investigation of batch effects in the replicate data.
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experiments showing resistance and sensitivity, the average estimation uncertainties varied across
target pathways. Interestingly, similar target pathways (e.g. chromatin histone methylation and chro-
matin histone acetylation) had very different levels of estimation uncertainty. Within each of these
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Figure 3. Relationship between AUC and uncertainties estimated from GPs across all experiments. (A) Coloured by difference between the AUC
estimated by sigmoid vs GP fits. (B) Coloured by Spearman correlation between cell viability and dose concentration in the raw data. Poorer
experiments (orange-red) result in greater uncertainty and positively correlated with cell viability increasing with higher dose. (C) Average uncertainty
and AUC for experiments with uncertain fits (estimation uncertainty >0.03) with drugs grouped by their target pathway. (D) Distribution of estimation
uncertainty for all drugs targeting chromatin histone methylation, chromatin histone acetylation, and mitosis and (E) for individual drugs.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. High estimation uncertainty independent of concentration range.
Figure supplement 2. Relationship between uncertainties and other experimental factors.
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target pathways have a bi-modal distribution representing compounds that have low uncertainty in
the cases of clear sensitivity or resistance, and high uncertainty in the cases of partial responders
(Figure 3E). Both chromatin histone methylation drugs in particular had a much longer right tail
towards higher estimation uncertainties that are associated with poor experimental readouts, or pos-
sibly off-targets.
Curve fits using Gaussian Processes can help identify clinically relevant
biomarkers
The IC50 values are highly conconcordant for sigmoid and GP-curve fittings, showing an average
weighted Pearson correlation of 0.88 (95% CI [0.85; 0.91]) across individual drugs, and cancer types
(Figure 4A). Strong agreement is found when true responding cell lines were observed in the screen
(Figure 4B). For example, if >10% of cell lines responded within the concentration range, that is
IC50 <maximum tested concentration, then a weighted Pearson correlation >0.75 was consistently
achieved for all drugs. We found positive correlations for all drugs, even when comparing exclusively
non-responding cell lines, where all the IC50 values are extrapolated beyond the maximum dosage
range. Drug-response values are concordantly fitted with both methods for sensitive cell lines
(Figure 4C, mean log10(IC50) in mM of 0.02 95% CI [ 0.05; 0.09]), whilst extrapolated non-respond-
ers tend to lead to more conservative and higher IC50 values fitted with GP (Figure 4C, mean log10
(IC50) in mM of 1.10, 95% CI [1.03; 1.18]). Whilst the average fits from the sigmoid and GP models
identify known clinical biomarkers, there are clearly differences for individual cell lines, especially
when the IC50 value has been extrapolated beyond the dosage range, that may help identify new
biomarkers. Alternatively, AUC values can be used to compare both curve fitting methods (Fig-
ure 4—figure supplement 1). Whilst known clinical biomarkers are recovered with AUC as a drug-
response metric, IC50 measures were used in the subsequent analysis as they retain direct relation-
ship with the drug concentration and are more interpretable.
To highlight the overall agreement of both curve fitting methods, we systematically tested 26 clin-
ically established biomarkers of drug response (Figure 4D, Figure 4—figure supplement 2A–C,
Supplementary file 1) using previously established association tests (Iorio et al., 2016), 24 of which
were significantly reproduced regardless of sigmoid or GP-curve fitting (10% FDR). For example,
both curve fittings captured the association of BRAF inhibitors (PLX4720, progenitor of vemurafenib;
and dabrafenib) with BRAF mutations in melanoma (Figure 4—figure supplement 3A–C;
Chapman et al., 2011). Dabrafenib is a potent BRAF inhibitor and in addition we detected BRAF
mutations as a sensitivity marker in thyroid carcinoma (Figure 4D, Figure 4—figure supplement
3D). Another example are the EGFR inhibitors, afatinib and gefitinib, that are concordantly corre-
lated with drug sensitivity in EGFR mutant cell lines in lung adenocarcinoma (Figure 4—figure sup-
plement 3E–G; Tamura and Fukuoka, 2005; Yang et al., 2012). ERBB2(HER2) amplification in
breast cancer was also recapitulated as a biomarker of sensitivity to the dual EGFR/ERBB2 inhibitor
lapatinib (Figure 4—figure supplement 3H; Konecny et al., 2006). Among the 26 clinical bio-
markers, we consistently found drug resistance of TP53 mutants to MDM2 inhibition with nutlin-3a in
five different cancer types (Figure 4E, Figure 4—figure supplement 3I–L). Overall, the majority of
expected clinical and preclinical biomarkers are reproduced, regardless of the drug-response curve
fitting method.
We concordantly and significantly identified six novel (not yet clinically established) drug sensitiv-
ity biomarkers (0.1% FDR) regardless of the applied drug-response curve fitting method. Investigat-
ing two different curve fitting algorithms, and retrieving the same biomarkers can be considered as
a test of robustness, which in our case concordantly highlighted non-gold standard associations for
prioritising experimental validation. For example, daporinad (also known as FK866 and APO866) is a
small-molecule inhibitor of nicotinamide phosphoribosyltransferase leading to inhibition of NAD+
biosynthesis. It has been clinically tested in melanoma (ClinicalTrials.gov Identifier: NCT00432107),
Refractory B-CLL (NCT00435084) and Cutaneous T-cell Lymphoma (NCT00431912), whilst showing
anti-proliferative effect in glioblastoma cell lines (Zhang et al., 2012). Therapeutic potential when
combining with other drugs used to treat gliomas (Lucena-Cacace et al., 2019; Lucena-
Cacace et al., 2017) has been suggested, whilst we additionally and concordantly identify EGFR
amplification as a biomarker (Figure 4F).
Another novel and concordant identified biomarker is doramapimod response (also known as
BIRB-796) in ARID2 mutant melanoma cell lines (Figure 4G). Doramapimod is a small-molecule p38
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Figure 4. Comparison of sigmoid and GP-curve fitting. (A) Weighted Pearson correlation of each drug within cancer types. (B) Comparing the
concordance of sigmoid and GP-curve fitting when stratifying for percentage of cell lines with IC50 value lower than maximum concentration. (C) IC50
value difference between GP and sigmoid curves. Grey histogram represents frequency distribution of the IC50 value difference between GP and
sigmoid curves without stratification by within/outside the concentration range. (D) Drug-response biomarker comparison based on both curve fittings
(sigmoid vs GP). The Benjamini-Hochberg adjusted p-values are in log10 scale and signed based on the direction of the effect size (Cohen’s d).
Additional biomarker examples for (E) diffuse large B-cell lymphoma (DLBCL) treated with nutlin-3a (MDM2 inhibitor) and stratified by TP53 mutants; (F)
Low grade glioma (LGG) treated with daporinad (NAMPT inhibitor) and stratified by EGFR amplification; (G) Skin cutaneous melanoma (SKCM) treated
with doramapimod (p38 and JNK2 inhibitor) and stratified with ARID2 mutations.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Comparison of GP and Sigmoid curve fitting using AUCs.
Figure supplement 2. Comparison of sigmoid and GP-curve fitting using IC50s.
Figure supplement 3. Drug-response biomarker comparison based on both curve fittings.
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MAPK inhibitor and has been reported in different cancer types (in combination with other drugs)
including cervical cancer, paracrine tumours and myeloma (Jin et al., 2016; Yasui et al., 2007).
ARID2 is part of chromatin remodelling complex and is involved in DNA repair in hepatocellular car-
cinoma cells (Oba et al., 2017) and enriched in melanomas (Ding et al., 2014; Hodis et al., 2012).
In conclusion, different curve fitting approaches lead to concordantly and novel identified bio-
markers, thereby increasing the robustness in those findings, and consequently enabling to prioritise
hypotheses.
Improved biomarker detection by taking into account uncertainty in a
Bayesian framework
Since both Bayesian and frequentist methods can be used to prioritise biomarkers for further testing,
we compared association statistics (posterior probabilities and q-values) from both statistical meth-
ods. We observed a number of cases where the Bayesian and ANOVA tests disagree (Figure 5A;
Supplementary file 2). For instance, BRAF mutations in colorectal cancer were detected as a sensi-
tivity biomarker for dabrafenib by the Bayesian test, but less significant by the ANOVA test. This
association had been repeatedly reported in in vitro models (Iorio et al., 2016; Rees et al., 2016)
and also found in melanoma cases (Chapman et al., 2011), whilst not in colorectal cancer patients
due to feedback activation of ERK-signalling mediated via EGFR (Corcoran et al., 2018;
Prahallad et al., 2012). We note in Figure 5B that the Bayesian test takes advantage of the addi-
tional information that sensitive mutant cell lines have low estimation uncertainty, whilst the small
number of resistant mutant cell lines have high estimation uncertainty, causing them to have less
influence on the biomarker detection. On the other hand, the ANOVA model detected the KRAS
copy number alteration as a resistance biomarker for lenalidomide (immunomodulatory drug) partial
sensitivity in skin cutaneous melanoma (SKCM), whilst not detected by our Bayesian approach. Whilst
on the linear IC50 scale there is some difference between the small number of mutant cell lines and
wildtypes, the Bayesian model considered that the estimated responses of the mutant cell lines had
high uncertainty (Figure 5C). Additionally, a comparison of the uncertainty estimates for the GP and
the Sigmoid curve fitting methods revealed that both display concordant results (Figure 5B and C;
Figure 5—figure supplement 1); However, the Sigmoid curve fitting method (Materials and meth-
ods; Vis et al., 2016) underestimates variance of non-responding cell lines rendering the GP
approach superior. The dosages within Figure 5B and C were rescaled to prevent the need for
adapting the length-scale hyperparameter to the maximum dosage. IC50 values were back-trans-
formed to the log10 drug dosage scale to make comparisons with (Iorio et al., 2016) (see Materials
and methods). Whilst discrepancies between Bayesian and ANOVA tests have to be taken with cau-
tion, they may highlight novel biological insights which would be missed when applying only a single
model.
Discussion
The GP approach developed in this research has several advantages compared to the traditional
approach of fitting sigmoidal drug-response curves. Firstly, these flexible, non-parametric models
can be used to fit a wider variety of dose-response curves than the parametric sigmoidal models,
for example curves of unexpected shapes may reflect biological signals of off-target effects. Sec-
ondly, the GP models provide straightforward uncertainty quantification of any summary statistic
that can be calculated on a dose-response curve, a fact that we take advantage of in developing our
hierarchical Bayesian model for biomarker testing. Thirdly, the GP model can deal with outlying
measurements better than a sigmoidal model, due to formulating it as a mixture model with one
component representing the latent GP process of the drug response, and the second component
accounting for outliers.
In contrast to other GP-based models in Tansey et al., 2018, our approach is highly interpret-
able, as we do not integrate the biomarkers into the model estimation in a non-linear fashion, but
instead proceed in a two-step approach that first fits our Gaussian process model to the dose-
response curves, and then uses the derived summary statistics and uncertainty measures to perform
biomarker detection. Thus, we can take advantage of the flexibility of the Gaussian process without
the complexity of fitting a non-linear neural network to enable prediction from molecular
measurements.
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Figure 5. Comparison of Bayesian testing and ANOVA using the GP IC50 estimates. (A) Scatterplot of biomarker
associations with IC50 drug response. The y-axis shows the negative log10 transformed posterior probability of a
sign change in the effect under the Bayesian testing model, whilst the x-axis shows the negative log10 of the
q-value from ANOVA testing. The size of the circles is proportional to the number of mutants or copy number
variations in the given type of cancer cell line. (B) GP estimates for the mean and standard deviation of the log
(IC50) from colorectal cell lines tested with BRAF inhibitor dabrafenib, which showed significant association with
BRAF mutation in the Bayesian test. (C) Estimated IC50 and its uncertainty for skin cutaneous melanoma cell lines
tested with the immunomodulatory drug lenalidomide, which showed significant association with KRAS copy
number alteration in the ANOVA test. Black vertical lines show the location of the maximum experimental drug
dosage. Dose-response curve of the (D) MDST8 colorectal cancer cell lines with BRAF mutation treated with
dabrafenib. The black dotted line represents the maximum concentration of the drug used to treat the cell lines.
The blue area represents the 95% confidence intervals in the dose-response fits. (E) Similar to (D) but for CHL-1
skin cutaneous melanoma cell lines with KRAS copy number alteration treated with lenalidomide.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Sigmoid curve fitting uncertainty.
Figure supplement 2. An overview of the cell viability values.
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The increased flexibility of the GP model comes at a price. Most notably, because we do not
impose a specific functional form, there are few constraints on the behaviour of the curve outside
the range of observed dosages. This leads to the counter-intuitive behaviour that the posterior
mean estimate of drug response can go up when extrapolating beyond the maximum dosage. Note,
however, that this goes along with a commensurate increase in the posterior variance (Figure 5D,E).
In other words, the model is highlighting that extrapolation beyond the observed dosage range is
highly uncertain, and the posterior mean estimate should not be relied on. It would be possible to
constrain this behaviour by introducing artificial data points at a high concentration, or less crudely
by imposing monotonicity constraints via virtual derivative observations (Riihimäki and Vehtari,
2010). However, these methods would limit the flexibility of our method and lead us to underesti-
mate the uncertainty of the posterior mean. An alternative approach is to constrain the Gaussian
process using generalised analytic slice sampling (Tansey et al., 2019), which integrates the con-
straints into the sampling process. Whilst theoretically appealing, this approach is not compatible
with the variational inference method that we have chosen for our work, and would lead to an unac-
ceptable increase in computational burden for fitting the dose-response curves.
We have systematically compared the application of GP to sigmoid models across a pan-cancer
drug screen. We demonstrated that our GP estimates of the IC50 values and their subsequently pre-
dicted biomarkers using ANOVA are reliable when compared to estimates from the sigmoid models.
In addition, the GP models provide useful information about the uncertainty associated with the
drug-response quantification. However, there is a crucial difference between estimation uncertainty
on a single experiment and observational uncertainty across multiple replicates of the same experi-
ment, which incorporates measurement error, technical and biological variation. We are interested in
the former to assess the quality of the fit, and therefore the reliability of the estimated IC50. We
hypothesized that estimation uncertainty characterises observational uncertainty within the dose
concentration range tested. However, extrapolating beyond the concentration range would be chal-
lenging due to the uncertainty in the behaviour of the dose-response curve in unobserved concentra-
tions. Imposing monotonicity may not be the best path in this case, but we avoid making this
assumption. Instead, our method defines a very large confidence interval for drug-response statistics
extrapolated beyond the maximum dose tested and we would additionally need to take the obser-
vation uncertainty between replicate experiments into account. We have verified this by applying
our estimation method to a replication data set of 26 drugs tested on 10 different cell lines, with 8
to 9 replicates for each drug-cell line experiment. We conclude that whilst estimation uncertainty is a
useful indicator for within-concentration IC50 values, it cannot be used as a proxy for observation
uncertainty when the IC50 is extrapolated beyond the tested concentration range. Indeed, overall
drug responses and biomarkers from independent drug screens were consistent when comparing
similar dose ranges (Haverty et al., 2016). Any difference between replicate experiments may be
due to batch effects or other unobserved factors that are not necessarily reflected in the estimation
error. Whilst previous studies have attempted to capture uncertainty by measuring the spread of the
residuals from the fitted curves, such as root mean square error, they were not able to capture these
false positive biomarkers by setting strict cutoffs (Cokelaer et al., 2018).
Whilst Bayesian posterior probabilities and ANOVA q-values are different statistical quantities for
measuring biomarker associations that should not be compared in absolute terms, we compared
these quantities in relative terms to prioritise biomarkers of response for further testing. Our Bayes-
ian biomarker model extends the classical ANOVA testing, since it is able to leverage the estimation
uncertainty of the IC50 values. We showed that taking estimation uncertainty into account in the
Bayesian model can lead to both inclusion and exclusion of putative biomarkers. For example, the
Bayesian model highlighted the association between BRAF mutation in colorectal cancer and BRAF
inhibitor response. Targeting BRAF signalling has recently been confirmed as a viable option for
metastatic colorectal cancer cases with BRAF mutations (Kopetz et al., 2019). In contrast, the Bayes-
ian model excluded a suggestion from ANOVA of association between KRAS mutation with lenalido-
mide response in melanoma. Lenalidomide has thus far had no clinical success in KRAS mutant cases
nor melanoma (Gandhi et al., 2013; Glaspy et al., 2009).
Although we systematically tested for drug-biomarker associations, we did observe common
behaviour for certain cell types or classes of drugs. The high uncertainty in the response estimates of
chromatin histone methylation targeting compounds for instance may be due to the large number of
factors contributing to epigenetic regulation of cells (Luo, 2015). It would be straightforward to
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extend the GP model to allow for sharing information across drugs or cell lines of similar class, by
using either shared hyperparameters or a hyperprior on the hyperparameters. We have not imple-
mented this approach in our work here as our aim was to show the advantage of fitting individual
drug-response using GPs, and extending the method to fitting multiple curves jointly would increase
the memory and computational requirements significantly. It is our hope to continue expanding the
suite to multiple dimensions of dose-response and biomarker prediction needed for drug combina-
tions, which is predominantly based on synergy modelling with either Loewe Additivity or Bliss Inde-
pendence (Di Veroli et al., 2016; Vlot et al., 2019). In cases where multiple statistical models
converge to concordant biomarkers, this increases the reproducibility of the evidence, potential for
clinical translatability and ultimately enables precision medicine.
The increasing utilisation of high-throughput drug screening for identifying effective new treat-
ments will necessitate the use of more powerful statistical and machine learning methods
(Toh et al., 2019). We have introduced an approach for quantifying the uncertainties of dose-
response using Gaussian Processes and further described how these uncertainties can be integrated
into statistical testing of biomarkers. For cancer treatments, our approach can help estimate the
uncertainty of dose-responses reported in the numerous drug screening studies by academic
(Ghandi et al., 2019; Holbeck et al., 2017; Iorio et al., 2016) and pharmaceutical laboratories
(Menden et al., 2019; O’Neil et al., 2016). This can provide more robust metrics for comparing
drug responses to identify the most potent ones and highlight sensitivity biomarkers that are more
likely to succeed clinically because they are associated with low uncertainty. The approach is also
generalisable beyond cancer to any disease and any dose-response measures. We hope that by con-
sidering response uncertainty and providing a probabilistic view of drug biomarkers, the risks associ-
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We analysed 1074 cancer cell lines tested with 265 compounds from a high-throughput screen
resulting in 225,384 experiments that were previously published (Iorio et al., 2016). Cell line data
was retrieved and is publically available via the GDSC website (Key Resources Table). All cell lines
were authenticated. Details for each cell line can be found at: https://www.cancerrxgene.org/help.
Compounds were tested with 5 to 9 titration points, whilst either diluted with 4- or 2-fold, respec-
tively. Cells were seeded on day zero, left in the microtiter plate for 24 hr to retain linear growth,
and consecutively treated for 3 days. After those 3 days of treatment, cellTiterGlo staining is used to
quantify ATP levels within each well. In parallel, untreated cells and blank wells were also measured
to estimate and normalise cell viability.
Compounds within the replicate study were screened across a seven point dose-response curve
with a half-log dilution and 1000 fold range. The duration of drug treatment was 72 hr and cell viabil-
ity was measured using CellTiter-Glo (Promega). Each cell line and compound pair was screened in
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technical triplicate, three assay plates generated simultaneously, and across three biological repli-
cates with 46 and 44 days between the first to second and second to third replicates respectively.
Cell viability measurements for these experiments can be found in Supplementary file 3.
Preprocessing
Prior to analysis, we scaled the raw observed fluorescent intensities for each drug/cell line combina-
tion using the observations from the blank and negative control wells as follows. Let R ¼ r1; r2:::; rnf g
be the observed intensities for n dosages. Let B be the mean of the intensities for the blank wells on
the same plate as the experiment, and C be the mean of the intensities of the negative control wells
(no drug added). Then the relative cell viability V can be calculated as:
V ¼ R   B
C   B
Relative cell viability values below 0 (n = 2646, Figure 5—figure supplement 2) were set to 0.
For the purpose of fitting the Gaussian process models, we additionally rescale the dosages to
avoid having to adapt the length-scale hyperparameter to the maximum dosage. We rescale the
log2-transformed dosages d ¼ d1; d2:::; dnf g as follows:
d0 ¼ d þ 1
max dð Þ þ 1
Note that IC50 values have been back-transformed to the log10 drug dosage scale for compara-
bility with those reported in Iorio et al., 2016.
Sigmoid drug-response model
The GDSC estimates in Iorio et al., 2016 were obtained using a sigmoid fit to the drug-response
curve, using the same pre-processing of the fluorescent intensities as described above. The particu-
lar sigmoid model used is the one described in Vis et al., 2016. In brief, if we have shape parameter
si and position parameter pij for cell line i and drug j , then cell viability can be represented as a func-
tion of dosage d:





Note that this allows for cell line/drug specific position parameters, but shape parameters that
only vary by cell line and are shared across drugs. The position parameter pij corresponds to the esti-
mated IC50 for cell line i and drug j. For full details, see Vis et al., 2016.
To estimate the uncertainty of the Sigmoid curve fitting, a random bootstrap sampling of 80% of
all treated cell lines available for each drug over 100 iterations was performed. The Sigmoid curve
fitting model from GDSC (Vis et al. 2013) estimates one scale parameter per drug across all treated
cell lines, thus the sampling creates variance in the response data. The standard deviation of the log
(IC50) estimates was computed to assess the model’s variance.
Gaussian process drug-response model
For simplicity, we drop the subscripts ij and present the combination. We model the drug response
y via a two-component Beta mixture such that:
Pðyjf; s1; 2; s2; pÞ ¼pBetaðyjF 1ðfÞ; s1 þð1þpÞBetaðyj2; s2ÞÞ
where Beta is the reparameterization of the Beta distribution in terms of the mean m and a scale
parameter s, and F 1 is the probit function (the inverse of the standard normal cumulative distribu-
tion function). Component one represents the drug response, which is driven by a latent Gaussian
process f, whilst component two represents outliers that deviate from the overall dose- response
trend. We set the scale parameters s1 ¼ 50 and s2 ¼ 11 and specify 2 ¼ 0:9 to reflect our belief that
outliers will mostly be erroneous measurements of resistance. We set p¼ 0:999 as we believe that
outliers are rare.
We place a standard Gaussian process prior on f, such that:
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Pðfjd; 	Þ ¼MVNðfjm; C	ðd; d
0ÞÞ
where m is the mean drug response, and C	ðd; d
0Þ is a covariance function with hyperparameters 	;
in practice we choose a combined linear-Matern3/2 as a flexible option, which avoids the excessive
smoothness of restrictions of the commonly used RBF kernel. Stein (1999) argues that this is a more
realistic representation for physical processes (Stein, 2012). Information sharing across drugs and
cell lines can be achieved via shared hyperpriors in a hierarchical model. For the application in this
paper joint inference with shared hyperpriors would be computationally difficult, and we choose to
instead empirically set the variance and length-scale parameters for the Matern to 0.2 and 0.3,
respectively, and the variance parameter for the linear kernel to 0.1.
Inference is performed using variational learning (Hensman et al., 2013), via the GPFlow software
(Matthews AG de and van der Wilk, 2017). We choose variational learning over alternatives such
as Markov chain Monte Carlo due to its speed, which allows us to process large drug-response pan-
els in a realistic time frame. Hyperparameters for the GP model were determined by manual tuning;
however, for other datasets, we could also envision a Bayesian model selection procedure which pla-
ces the variational inference in a variational-within-MCMC scheme where the MCMC moves update
the hyperparameters. If fixed hyperparameters are desired, one could use the maximum a posteriori
values. To avoid massive computational complexity, the MCMC scheme could be run on a represen-
tative subsample of cell lines.
Calculation of summary statistics
Summary statistics of drug response can be calculated straightforwardly by sampling from the poste-
rior of the Gaussian process (Supplementary file 4). Generally, let gðd; yÞ be a function that calcu-
lates a summary statistic t from a dose-response curve with dosages d and responses y, then we
can obtain a posterior estimate of the mean of the summary statistic by first sampling N dose-







A similar procedure can be used to calculate the posterior estimate of the standard deviation.
Although we can extract other response statistics from our curve fits, the most common are the
IC50 and the area under the drug-response curve (AUC). On the log2 dosage scale the dosages are








where m indexes over the n dosages. For the IC50, estimation for a single curve is complicated by
the fact that the curve may not cross the 50% viability threshold within the observed dosage range
(non-crossing sample). We therefore extrapolate the GP samples to 10 times the maximum (log2)
experimental dosage and specify gIC50ðd; yÞ as:
gIC50ðd; yÞ ¼ dm suchthatym ¼ 0:5 if 9ym  0:5
Note that this ignores samples where for all dosages, ym  0:5; one could devise a multivariate suf-
ficient statistic that takes this information into account, but we have found that in general there is a
reasonable amount of correlation between gIC50ðd; yÞ and the number of non-crossing samples for a
given cell line/drug combination.
Comparison of GP and sigmoid IC50 values
Concordance between IC50 values based on sigmoid and GP-curve fitting is quantified with Pearson
correlation for each drug. To account for tissue specificity and the varying number of cell lines
assessed per tissue type, we employed the average weighted Pearson correlation (pw) of the sig-
moid-curve versus GP-curve fitted IC50 values for the individual cancer types (i).
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where pi is unweighted Pearson correlation within a cancer type (i) and a total number of tested can-
cer types is N ¼ 30. For a given drug and tissue type combination, at least 10 cell lines need to be
treated (ni  10).
Differences in IC50 values for each drug-response value j were consistently defined as
dfi ¼ IC50j;GP   IC50j;sigmoid
with a total number of tested cell line and drug combinations equalling to Nj ¼ 171;937.
Bayesian biomarker testing
Standard statistical approaches for testing the influence of biomarkers on drug response mostly rely
on analysis of variance (ANOVA) testing. An ANOVA can be understood as a linear model of the
dependent variable i (in this case, a summary measure of drug response such as IC50):
gi ¼ aþbziþgxi þ i
where xi is an indicator variable denoting the group membership of data point i. In our application,
the data points are cell lines, zi indicates group membership, for example the mutation status of a
given SNP, and xi indicates any other covariates that we wish to correct for, such as tissue type. The
parameter a captures the global mean of the drug response, whilst b captures the effect of mutation
status on the drug response, g is the effect of covariates, and i is independent Gaussian noise.
This model, whilst useful, fails to account for the fact that our Gaussian process model provides
estimates si of the uncertainty (or standard error) associated with the mean IC50 estimates gi. In
order to make use of these uncertainty estimates, we take an idea from Bayesian meta-analysis, and
integrate them via a hierarchical model:
gi ~Nði; s2i Þ
i ~Nðaþbziþgxi; s2Þ
where i is the mean drug-response estimate for cell line i, and s
2 is the variance across cell lines
(the variance of i in the ANOVA example). Note that this model can be reduced to:
gi ~Nðaþbzi þgxi; s2i þs2Þ
We further specify a Gaussian prior b~Nð0; 0:1Þ on the effect size parameter to discourage false
positives and reflect our prior belief that most mutations are not associated with drug response. We
also place an exponential prior s2 ~Expð10Þ to regularize the variance parameter. Finally,
a~Nð0;t 2Þ is a Gaussian prior on the global mean with standard error t ~Gammað1; 1Þ. Early explor-
atory results showed that using the estimates of si directly placed too much weight on experiments
with very low estimation uncertainty, leading to unrealistic posterior estimates of the effect size b.
To attenuate this, we used a transformed estimate sci , where the effect of parameter c was explored
over the range [0,1], and empirically set to 0.25 for the results reported in this paper. The main tune-
able hyperparameter is the scaling parameter c, as the model is robust to changes to the parameters
for the sparse priors on b and s2. Setting this hyperparameter is straightforward, as we can use a
simple line search to find a value that optimally trades off between disregarding the uncertainty esti-
mates (c = 0) and placing too much weights on estimates with low uncertainty (c >= 1). One way to
determine the optimal value for c is to randomly permute the biomarker labels, and reduce c until
the false positive rate is below some acceptable threshold.
Inference in this model is performed using Hamiltonian Monte Carlo via the Stan software pack-
age Carpenter, 2017. We report the posterior mode of b as well as the posterior probability of
observing b>0 (if the posterior mode is positive) or b<0 (if the posterior mode is negative).
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Data availability
All data is available through the GDSC downloads portal (ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/
releases). Raw dose response data have been deposited in GDSC under v17a_public_raw_data.csv
(ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17a_public_raw_data.csv). Sigmoid
fitted dose-response curves have been deposited in GDSC under v17_fitted_dose_response.csv
(ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-6.0/v17_fitted_dose_response.xlsx). Cell
line genomics data have been deposited in GDSC under GDSCtools_mobems.zip (ftp://ftp.sanger.
ac.uk/pub4/cancerrxgene/releases/release-8.0/GDSCtools_mobems.zip). Cell line identity details
have been deposited in GDSC under Cell_Lines_Details.xlsx (ftp://ftp.sanger.ac.uk/pub4/cancer-
rxgene/releases/release-7.0/Cell_Lines_Details.xlsx). Drug compound details have been deposited in
GDSC under screened_compunds_rel_8.2.csv (ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/
release-6.0/Screened_Compounds.xlsx).
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asymmetry parameter for curve-fitting in single-chemical and mixture toxicity assessment. Toxicology 292:156–
161. DOI: https://doi.org/10.1016/j.tox.2011.12.006, PMID: 22210403
Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI. 2016. Combenefit: an
interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32:2866–2868.
DOI: https://doi.org/10.1093/bioinformatics/btw230, PMID: 27153664
Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC,
Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, et al.
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